Today: 13 June 2026
Browse Category

NYSE:BBWI 20 November 2025

Bath & Body Works (BBWI) Stock Hit by Q3 2025 Miss, Holiday Sales Warning and New ‘Consumer First’ Turnaround Plan

Bath & Body Works (BBWI) Stock Hit by Q3 2025 Miss, Holiday Sales Warning and New ‘Consumer First’ Turnaround Plan

Bath & Body Works shares fell sharply Thursday after the company missed third-quarter earnings estimates, cut its full-year forecast, and warned of weaker holiday demand. Net sales for Q3 dropped 1% to $1.594 billion, with net income falling to $77 million from $106 million a year ago. The stock traded near $21, down 46% year to date. The company now expects full-year sales to decline and EPS of at least $2.83.
20 November 2025
··

Stock Market Today

  • Rezolve AI Plans $300 Million Buyback Amid Valuation Debate
    June 12, 2026, 6:08 PM EDT. Rezolve AI (RZLV) is under the spotlight after announcing a US$300 million share buyback funded from cash reserves. Trading at US$2.53, the stock gained 5.86% in one day but shows a 9.96% decline over 30 days. The company reaffirmed its 2026 revenue guidance and appointed a new Chief Marketing Officer, signaling confidence in growth. A popular market narrative values the stock at US$10.00, suggesting significant undervaluation, driven by potential recurring revenue growth and improved margins. However, risks around ambitious revenue targets and vendor integrations persist. Contrarily, some models, like Simply Wall St's discounted cash flow analysis, value the stock as low as US$0.15. Investors face a wide valuation gap, weighing Rezolve AI's future growth prospects against execution risks.

Latest articles

Alumis Shares Surge 16% as Traders Eye New Drug Move

Alumis Shares Surge 16% as Traders Eye New Drug Move

12 June 2026
Alumis soared 15.55% to $24.15 on double average volume after strong analyst support and late-stage psoriasis data, but remains a high-risk, loss-making biotech with no approved products; key investor focus is on Phase 2b lupus data due Q3 and a planned psoriasis NDA filing in Q4, with future stock moves hinging on these clinical and regulatory milestones.
Maase Shares Rise After Times Good Filing

Maase Shares Rise After Times Good Filing

12 June 2026
Maase Inc. (MAAS) jumped 15.73% to $14.86 after a June 12 SEC filing revealed its Times Good acquisition brings AI-computing revenue growth potential but also losses, negative cash flow, and a going-concern warning; investors await proof Maase can turn its AI push into funded projects and improved financials.
Go toTop